ZFP62 and COVID-19: Artenimol is an interesting prediction for targeting ZFP62, since this protein is involved in the positive regulation of transcription by RNA polymerase II, which is known to act as an RNA-dependent RNA polymerase (RdRP), and inhibiting RdRP activity is the known mode of action of other widely used COVID-19 drugs, such as remdesivir [27].